Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHENDIMETRAZINE TARTRATE vs DESFLURANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phendimetrazine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the hypothalamus to release norepinephrine, leading to decreased food intake and increased energy expenditure. It is a prodrug that is metabolized to phenmetrazine, which is a potent central nervous system stimulant with amphetamine-like effects.
Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.
Management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction,Off-label: treatment of obesity with comorbid conditions where weight loss is beneficial
Maintenance of general anesthesia for inpatient and outpatient surgery in adults and children,Induction of anesthesia in adults and pediatric patients
Oral: 35 mg twice daily or three times daily, 1 hour before meals; extended-release: 105 mg once daily in the morning.
Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).
Terminal half-life 3-4 hours; clinical context: requires multiple daily dosing
Terminal elimination half-life is 3.5–4.5 minutes (context-sensitive half-life after prolonged anesthesia can be longer due to distribution, but true elimination is rapid due to low blood/gas partition coefficient).
Primarily metabolized in the liver via N-demethylation to its active metabolite, phenmetrazine. Other metabolites include phendimetrazine N-oxide and norphenmetrazine. CYP450 enzymes are involved, though specific isoforms not well characterized.
Minimal hepatic metabolism (<0.02%) via CYP2E1; primarily eliminated unchanged by the lungs.
Primarily renal (≥70% unchanged) with minor biliary/fecal elimination (<10%)
Primarily eliminated via exhalation; minimal hepatic metabolism (<0.02%). Renal excretion of metabolites negligible. >99% excreted unchanged by lungs.
10-15% bound to albumin
Approximately 5–10% bound to plasma proteins (primarily albumin).
2-3 L/kg; indicates extensive tissue distribution
Vd approximately 0.2–0.5 L/kg (small, reflecting limited tissue distribution; consistent with lipophilic but rapidly equilibrating profile).
Oral: approximately 80-90%
Inhalation: ~100% bioavailable into systemic circulation via lungs.
Contraindicated in severe renal impairment (GFR < 30 m L/min). No specific dose adjustments for mild-moderate impairment; use with caution.
No dosage adjustment required for renal impairment; desflurane is minimally metabolized and not dependent on renal excretion.
Not recommended in Child-Pugh class B or C. Use with caution in mild impairment.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to potential for increased hepatotoxicity, but no dose modification guidelines exist.
Not recommended for children under 12 years; safety and efficacy not established.
Induction: 3-12% inhaled (up to 18% for mask induction); maintenance: 3-6% inhaled; adjust based on age and response; higher MAC requirements in infants.
Start at lower end of dosing range; monitor for increased sensitivity and cardiovascular effects.
Reduce dose by 20-30% compared to younger adults; typical maintenance 2-5% inhaled; lower MAC (approx 4.5% at 65 years); monitor for hypotension and bradycardia.
Phendimetrazine is not approved for use in patients with a history of drug abuse or dependence. It has a high potential for abuse and may lead to dependence. Use caution in patients with cardiovascular disease or hypertension.
Desflurane is not indicated for induction of general anesthesia in pediatric patients due to a high incidence of laryngospasm and upper airway adverse events.
Increased risk of pulmonary hypertension and valvular heart disease; monitor for dyspnea, chest pain, or edema. Tolerance may develop; discontinue if tolerance occurs. May impair ability to perform hazardous tasks. Use with caution in patients with hypertension, diabetes, or glaucoma. Do not use with MAOIs or within 14 days of discontinuation.
Malignant hyperthermia,Respiratory depression and airway complications,Cardiovascular depression (hypotension, bradycardia),QT prolongation,Hepatotoxicity (rare),Rising carbon monoxide levels with dry absorbents,Neurotoxicity in pediatric patients,Renal toxicity (rare)
Hypersensitivity to phendimetrazine or any component of the formulation, advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma, agitated states, history of drug abuse, during or within 14 days of MAOI therapy
Known sensitivity to desflurane or other halogenated anesthetics,History of malignant hyperthermia,Refractory hypovolemia,Increased intracranial pressure (relative),Concomitant use with adrenergic agents (risk of arrhythmias)
Avoid alcohol and excessive caffeine (coffee, tea, energy drinks) as they may increase CNS stimulation and risk of side effects. Take with or without food; high-fat meals may delay absorption of extended-release formulations. Maintain a calorie-reduced diet as part of a comprehensive weight loss plan.
No known food interactions. However, patients should follow preoperative fasting guidelines (nil per os for at least 2 hours for clear liquids and 6-8 hours for solid foods) to reduce the risk of pulmonary aspiration during anesthesia.
First trimester: Limited data; potential for increased risk of oral clefts. Second/third trimester: Anorexiant effects may cause fetal growth restriction; avoid use due to maternal hypertension risk.
Desflurane is not associated with major congenital malformations in the first trimester, but use in the second and third trimesters may cause fetal depression, decreased fetal heart rate variability, and neonatal respiratory depression. It is pregnancy category B, but caution is advised.
Excreted in breast milk; M/P ratio unknown. Contraindicated in breastfeeding due to potential CNS stimulation and cardiovascular effects in infant.
Desflurane is minimally excreted into breast milk; M/P ratio is unknown. It is considered compatible with breastfeeding due to rapid elimination from the mother and low oral bioavailability in the infant. However, monitor for neonatal sedation.
Contraindicated in pregnancy; no dose adjustments recommended. Avoid use due to risks of hypertension and potential teratogenicity.
No specific dose adjustment for desflurane in pregnancy, but the minimum alveolar concentration (MAC) is reduced by approximately 25-40% due to increased progesterone and other factors. Lower doses may be required to achieve desired anesthetic depth.
Phendimetrazine tartrate is a schedule III controlled substance with high abuse potential. It is approved only for short-term (up to 12 weeks) monotherapy for exogenous obesity. Contraindicated in patients with glaucoma, hyperthyroidism, agitated states, history of drug abuse, or cardiovascular disease. Taper dose to avoid withdrawal. Monitor blood pressure and heart rate; may cause pulmonary hypertension. Avoid use with MAOIs (risk of hypertensive crisis) and within 14 days of discontinuation.
Desflurane has the lowest blood-gas partition coefficient among volatile anesthetics, resulting in the fastest onset and emergence. Its pungent odor limits use for inhalation induction, especially in children. Due to its high vapor pressure, a specialized heated vaporizer is required. Desflurane can cause sympathetic nervous system activation at high concentrations, leading to tachycardia and hypertension. It is metabolized minimally (0.02%), but can produce carbon monoxide when exposed to dried CO2 absorbents; desiccated absorbents should be avoided. Malignant hyperthermia risk is present, so dantrolene should be available.
Take exactly as prescribed; do not increase dose or duration.,Take last dose of the day 4-6 hours before bedtime to prevent insomnia.,Do not crush or chew extended-release tablets; swallow whole.,Avoid driving or operating heavy machinery until you know how this medication affects you.,Report chest pain, shortness of breath, fainting, or leg swelling immediately.,Do not stop abruptly; follow your doctor's tapering plan.,Store securely; keep out of reach of others as this medication can be habit-forming.,Do not take with alcohol or other CNS stimulants.,Use with caution if you have high blood pressure, diabetes, or a history of depression.
You will receive desflurane gas through a mask or breathing tube to keep you asleep during surgery.,Desflurane has a strong smell; you may notice an odor as you fall asleep.,You will wake up quickly after the anesthetic is stopped, but you may feel drowsy or confused initially.,Potential side effects include nausea, vomiting, shivering, and a temporary increase in heart rate or blood pressure.,Inform your doctor if you have a personal or family history of malignant hyperthermia (a severe reaction to anesthesia).,Do not eat or drink before surgery as instructed to prevent aspiration.
"Concurrent use of buspirone and desflurane may potentiate the hypotensive and bradycardic effects of desflurane, increasing the risk of hemodynamic instability during anesthesia induction or maintenance. Buspirone's serotonergic activity can also lower seizure threshold, potentially interacting with the anesthetic properties of desflurane to cause perioperative seizures or arrhythmias. Clinically, this combination requires careful cardiovascular monitoring and dose adjustment of desflurane to avoid excessive hypotension, bradycardia, or delayed emergence."
"Concomitant use of Desflurane and Triprolidine may lead to enhanced central nervous system (CNS) depression and potential respiratory compromise. Desflurane, a volatile anesthetic, depresses the CNS and respiratory drive, while Triprolidine, a first-generation antihistamine, adds sedative and anticholinergic effects. This synergistic interaction increases the risk of excessive sedation, hypotension, and respiratory depression, particularly during induction or recovery from anesthesia. Clinically, patients may experience prolonged emergence, worsened cognitive function, and increased need for ventilatory support."
"Concomitant administration of desflurane, a volatile halogenated anesthetic, with oxprenolol, a non-selective beta-adrenergic receptor antagonist with intrinsic sympathomimetic activity, can lead to additive negative inotropic and chronotropic effects on the myocardium, resulting in significant hypotension and bradycardia. This interaction occurs because desflurane depresses myocardial contractility and heart rate directly, while oxprenolol blocks compensatory sympathetic responses, potentially compromising cardiac output and tissue perfusion. Clinicians should be vigilant for exaggerated cardiovascular depression, especially during induction or changes in anesthetic depth."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHENDIMETRAZINE TARTRATE vs DESFLURANE, answered by our medical review team.
PHENDIMETRAZINE TARTRATE is a Anorectic (Sympathomimetic) that works by Phendimetrazine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the hypothalamus to release norepinephrine, leading to decreased food intake and increased energy expenditure. It is a prodrug that is metabolized to phenmetrazine, which is a potent central nervous system stimulant with amphetamine-like effects.. DESFLURANE is a General Anesthetic that works by Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHENDIMETRAZINE TARTRATE and DESFLURANE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHENDIMETRAZINE TARTRATE is: Oral: 35 mg twice daily or three times daily, 1 hour before meals; extended-release: 105 mg once daily in the morning.. The standard adult dose of DESFLURANE is: Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHENDIMETRAZINE TARTRATE and DESFLURANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHENDIMETRAZINE TARTRATE is classified as Category C. First trimester: Limited data; potential for increased risk of oral clefts. Second/third trimester: Anorexiant effects may cause fetal growth restriction; avoid use due to maternal. DESFLURANE is classified as Category C. Desflurane is not associated with major congenital malformations in the first trimester, but use in the second and third trimesters may cause fetal depression, decreased fetal hear. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.